A Randomized, Sponsor-Open, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of RO7062931 With Single Ascending Doses in Healthy Volunteers and Multiple Doses and Modified Regimens in Virologically Suppressed Patients With Chronic Hepatitis B Virus Infection
Phase of Trial: Phase I
Latest Information Update: 25 Nov 2019
Price : $35 *
At a glance
- Drugs RO 7062931 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 21 Nov 2019 Status changed from recruiting to completed.
- 08 Nov 2019 Planned End Date changed from 15 Oct 2019 to 15 Nov 2019.
- 08 Nov 2019 Planned primary completion date changed from 15 Oct 2019 to 15 Nov 2019.